Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5608908 | 0.91 | ALDH1A1 (0.43) | PPM1BPTPN1PPP1CCTSHRMAPT | |
| SCHEMBL14924183 | 0.79 | PPM1B (0.45) | PPM1BPTPN1PPP1CCTSHRMAPT | |
| SCHEMBL5584078 | 0.78 | PPM1B (0.41) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL1862124 | 0.77 | TSHR (0.45) | PPM1BPTPN1PPP1CCTSHRMAPT | |
| SCHEMBL2387697 | 0.77 | TSHR (0.55) | PPM1BPTPN1PPP1CCTSHRALDH1A1 | |
| SCHEMBL2387693 | 0.77 | TSHR (0.55) | PPM1BPTPN1PPP1CCTSHRALDH1A1 | |
| SCHEMBL2387688 | 0.77 | TSHR (0.55) | PPM1BPTPN1PPP1CCTSHRALDH1A1 | |
| SCHEMBL11545787 | 0.77 | TSHR (0.55) | PPM1BPTPN1PPP1CCTSHRALDH1A1 | |
| SCHEMBL5317413 | 0.77 | TSHR (0.55) | PPM1BPTPN1PPP1CCTSHRALDH1A1 | |
| SCHEMBL5608038 | 0.75 | ALDH1A1 (0.38) | PPM1BPTPN1PPP1CCALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12252497-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-03-18 | — | — | US | disclosed |
| US-20240277796-A1 | METHODS FOR INHIBITING RAS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-08-22 | — | — | US | disclosed |
| US-20240262847-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-08-08 | — | — | US | disclosed |
| EP-4346898-A1 | METHODS FOR INHIBITING RAS | Revolution Medicines, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4334324-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4334325-A1 | RAS INHIBITORS FOR THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20220396589-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2022-12-15 | — | — | US | disclosed |
| WO-2022251292-A1 | METHODS FOR INHIBITING RAS | Revolution Medicines, Inc. (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022235866-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022235870-A1 | RAS INHIBITORS FOR THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396589-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | PPM1B 537/4885PTPN1 498/4885PPP1CC 613/4885 |
| US-20240262847-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | KRAS, NRAS, HRAS | PPM1B 323/4885PTPN1 161/4885PPP1CC 996/4885 |
| US-12252497-B2 | Ras inhibitors | KRAS, NRAS, HRAS | PPM1B 537/4885PTPN1 498/4885PPP1CC 613/4885 |
| US-20240277796-A1 | METHODS FOR INHIBITING RAS | KRAS, HRAS, NRAS | PPM1B 421/4885PTPN1 593/4885PPP1CC 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.